273 related articles for article (PubMed ID: 35016637)
1. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
Chen SC; Huang YH; Chen MH; Hung YP; Lee RC; Shao YY; Chao Y
BMC Cancer; 2022 Jan; 22(1):55. PubMed ID: 35016637
[TBL] [Abstract][Full Text] [Related]
2. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis.
Cao YZ; Zheng GL; Zhang TQ; Shao HY; Pan JY; Huang ZL; Zuo MX
World J Gastroenterol; 2024 Jan; 30(4):318-331. PubMed ID: 38313229
[TBL] [Abstract][Full Text] [Related]
4. The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE.
Kimura Y; Kaneko R; Yano Y; Kamada K; Ikehara T; Nagai H; Sato Y; Igarashi Y
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1797-1805. PubMed ID: 32592380
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
6. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma.
Kuo HY; Chiang NJ; Chuang CH; Chen CY; Wu IC; Chang TT; Tsai HM; Lin YJ
Oncol Res Treat; 2020; 43(5):211-220. PubMed ID: 32101878
[TBL] [Abstract][Full Text] [Related]
7. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.
Zhang B; Tao B; Li Y; Yi C; Lin Z; Ma Y; Han J; Shao W; Chen Z; Lin J; Chen J
Eur J Intern Med; 2023 May; 111():37-46. PubMed ID: 36588054
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
[TBL] [Abstract][Full Text] [Related]
9. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma.
Peng TR; Wu CC; Chang SY; Chen YC; Wu TW; Hsu CS
Int Immunopharmacol; 2022 Nov; 112():109223. PubMed ID: 36084538
[TBL] [Abstract][Full Text] [Related]
11. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis.
Zhang XP; Chai ZT; Gao YZ; Chen ZH; Wang K; Shi J; Guo WX; Zhou TF; Ding J; Cong WM; Xie D; Lau WY; Cheng SQ
HPB (Oxford); 2019 Dec; 21(12):1687-1696. PubMed ID: 31153833
[TBL] [Abstract][Full Text] [Related]
12. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
15. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study.
Su K; Guo L; Ma W; Wang J; Xie Y; Rao M; Zhang J; Li X; Wen L; Li B; Yang X; Song Y; Huang W; Chi H; Gu T; Xu K; Liu Y; Chen J; Wu Z; Jiang Y; Li H; Zeng H; Wang P; Feng X; Chen S; Yang B; Jin H; He K; Han Y
Front Immunol; 2022; 13():972503. PubMed ID: 36211350
[TBL] [Abstract][Full Text] [Related]
16. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis.
Chen S; Shi M; Shen L; Qi H; Wan W; Cao F; Xie L; Wu Y; Chen G; Mo J; Zhu G; Ye D; Zhang Y; Feng Z; Xu L; Fan W
Int J Hyperthermia; 2020; 37(1):384-391. PubMed ID: 32323585
[No Abstract] [Full Text] [Related]
17. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience.
Wu WC; Lin TY; Chen MH; Hung YP; Liu CA; Lee RC; Huang YH; Chao Y; Chen SC
Invest New Drugs; 2022 Aug; 40(4):789-797. PubMed ID: 35477812
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
19. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
Zhao S; Zhou M; Wang P; Yang J; Zhang D; Yin F; Song P
Technol Cancer Res Treat; 2022; 21():15330338221133640. PubMed ID: 36259214
[No Abstract] [Full Text] [Related]
[Next] [New Search]